From localized NCD trials to a forest disease vaccine and a quantum leap in MedTech — India’s biomedical establishment is rewriting the terms of its dependence on Western science
There is a quiet but consequential reckoning underway in Indian medicine. For decades, the clinical protocols guiding treatment of diabetes, hypertension, cardiovascular disease, and other non-communicable conditions in Indian hospitals have been derived predominantly from trials conducted in the United States, the United Kingdom, and Western Europe — populations whose genetic profiles, dietary patterns, disease seasonality, and healthcare access bear limited resemblance to those of the 1.4 billion people they are now used to treat. In early 2026, India’s apex biomedical research body moved to correct this with institutional force. The Indian Council of Medical Research (ICMR) has launched a coordinated, multi-front initiative that encompasses localized clinical trials for chronic diseases, an indigenous MedTech grant mechanism, and — most dramatically — the entry of a fully home-built vaccine against a regional viral hemorrhagic fever into human clinical testing. Taken together, these developments constitute what may be recognized, in retrospect, as the beginning of India’s era of medical sovereignty.
Evidence for India, by India
The Indian Council of Medical Research has called for a decisive shift toward large, multi-centre clinical trials that generate India-specific evidence for treating lifestyle and chronic diseases, moving away from heavy reliance on Western data. The initiative focuses on conditions such as diabetes, heart disease, cancer, and other non-communicable diseases that account for a growing share of the country’s disease burden.
The institutional logic underpinning this shift is both scientific and epidemiological. Health experts note that treatments proven effective in Western populations do not always translate seamlessly to Indian patients because of differences in genetics, diet, climate, disease patterns, and access to care. Cardiologist Dr. Ambuj Rao of AIIMS Delhi highlighted an ongoing pan-India influenza vaccine trial in heart attack patients as an example of why local data is essential, noting that India has a distinct flu season and public health profile that cannot be mapped directly from Western studies.
The operational architecture of the initiative is built around the ICMR Clinical Care Excellence Initiative, which is designed to support high-impact, academic or non-regulatory randomized controlled trials that require data from multiple sites to achieve statistical significance and generalizability for addressing NCDs, with participating networks required to involve a minimum of five hospitals. Officials say participating hospitals will be required to run trials independently, maintain standardized digital records, and share data transparently — a framework that could reduce dependence on pharmaceutical-led global research and strengthen domestic research capacity. The Expression of Interest deadline of April 15, 2026 signals that this is an initiative gathering momentum, not merely a policy aspiration.
The implications for patients are direct. Public health experts believe the programme could have a tangible impact on families managing chronic disease, as even modest adjustments to treatment protocols — when backed by Indian data — can improve outcomes and lower out-of-pocket spending. If the initiative succeeds, clinicians say it could mark a turning point where prescriptions in India are guided primarily by evidence generated from Indian patients, rather than assumptions imported from other health systems.
MedTech Indigenization
Complementing the clinical trials initiative is the ICMR-Intramural MedTech Call 2.0, a grant scheme targeting medical device and diagnostic innovation within ICMR’s own research network. The scheme supports projects within ICMR institutes that demonstrate a technology readiness level of at least 3 — indicating an established proof of concept — or offer solutions that significantly reduce costs compared with existing alternatives, while commercialization strategies must accompany project plans. The dual focus on technological novelty and cost reduction is calibrated deliberately toward integration with public health programmes such as Ayushman Bharat, where affordability is not an option but a precondition of utility. The initiative seeks to strengthen India’s capacity to design, develop, and translate innovative technologies that address priority health needs, while reducing dependency on imported medical devices and systems.
Forest Fever to Human Trial
Of all the developments in India’s current biomedical moment, none carries a more concentrated narrative force than the initiation of Phase I human clinical trials for a fully indigenous vaccine against Kyasanur Forest Disease — popularly known as monkey fever.
KFD is a regional infectious disease endemic to the Western Ghats, affecting states including Karnataka, Tamil Nadu, Kerala, Goa, and Maharashtra. The Indian Immunologicals Limited (IIL) and ICMR-National Institute of Virology (NIV) are working collaboratively to develop a fully indigenous two-dose adjuvanted inactivated vaccine, administered 28 days apart. The disease — a tick-borne viral haemorrhagic fever transmitted primarily by Haemaphysalisspinigera ticks — has long represented precisely the category of regional endemic pathogen that global pharmaceutical companies, oriented toward high-volume markets, have had little commercial incentive to address. India has addressed it through the mission-mode model that has served its vaccine programme well: a government-commissioned, institution-led, industry-manufactured pipeline, moving from laboratory to clinic with the urgency that endemic disease demands.
The vaccine has been successfully developed, and animal challenge and toxicity studies have been completed. The GLP-grade vaccine material has been manufactured, and a Phase I human clinical trial has been initiated following approval from the Central Drugs Standard Control Organisation (CDSCO). The development marks a crucial step toward strengthening India’s response to a regionally endemic tick-borne viral infection that has long troubled communities in the Western Ghats. The primary objectives at this stage are to assess safety, monitor side effects, and determine an appropriate dosage range before moving to larger studies that evaluate efficacy in at-risk populations.
The Hyderabad connection is notable: Indian Immunologicals Limited, a subsidiary of the National Dairy Development Board based in Hyderabad, brings manufacturing credibility honed across decades of vaccine production for India’s Universal Immunization Programme. That institutional pedigree, combined with the NIV’s deep virology expertise, makes this partnership a model worth watching as India builds out its indigenous vaccine pipeline.
DBT’s Bio-RIDE and the Pipeline Beyond KFD
The KFD vaccine does not stand alone. The Bio-RIDE scheme — Biotechnology Research Innovation and Entrepreneurship Development — consolidates and significantly expands India’s biotech R&D funding, with an allocation of Rs. 9,197 crore for the period covering 2021-22 to 2025-26, with enhanced allocations expected for the subsequent cycle. Under this umbrella, the Department of Biotechnology is prioritizing vaccine development for Mpox through the Translational Health Science and Technology Institute (THSTI) and for malaria through the National Institute of Immunology (NII) — diseases that represent both global and domestic burdens. A Shigella vaccine, co-developed by ICMR and Hilleman Labs, is advancing toward scaling and commercialization.
What India is building, across these simultaneous fronts, is not merely a portfolio of research projects. It is the institutional infrastructure for medical self-determination — the capacity to ask its own questions, design its own answers, and produce its own tools for a population whose biological and social reality has for too long been treated as a footnote to Western clinical science. The ICMR’s Clinical Care Excellence Initiative, the MedTech Call 2.0, and the KFD vaccine’s entry into human trials are three distinct expressions of a single underlying conviction: that the evidence which guides the health of Indian patients must originate from Indian patients. This is not medical nationalism; it is medical rationality. The two, at this particular historical juncture, happen to coincide.
– Rithvisha Kiran
